Abstract: Disclosed herein are methods and compositions related to determining one or more biomarkers in Full-Length Excised Linear Intron RNAs (FLEXI RNAs) and Intron RNA fragments. These FLEXI RNAs and Intron RNA fragments can be indicative of a specific characteristic. trait. disease. disorder or condition. FLEXI RNAs and Intron RNA fragments can be used to establish a predictive bio-marker. a diagnostic biomarker, a prognostic biomarker, or a biomarker that relates to drug interaction, drug response, or to a heritable condition. These biomarkers can then be used to treat. monitor. or inform patients.

Abstract: Provided herein are nucleic acid constructs and methods for producing or enhancing the production of group II intron RNP particles in eukaryotic cells. The present methods comprise introducing at least one nucleic acid construct comprising a nucleic acid encoding a modified or wild type group II intron RNA and a wild-type or modified group II intron-encoded protein into the eukaryotic cell, and maintaining the cell under conditions that allow for expression of the group II intron RNA and the group II intron-encoded protein in the cell. The nucleic acid encoding the group II intron RNA is operably linked to an RNA polymerase I, an RNA polymerase II, or an RNA polymerase III promoter, and the nucleic acid encoding the group II intron-encoded protein is operably linked to an RNA polymerase II promoter. In certain embodiments, a subcellular localization signal is attached to the group II intron-encoded protein.